Live Biotherapeutics Drug Discovery Service for HIV
Overview
Acquired immunodeficiency syndrome (AIDS) is a serious chronic disease involving the development of opportunistic infections. This is the final stage of disease progression in human immunodeficiency virus (HIV) infection and can be sexually transmitted. HIV infection leads to disruption of the gastrointestinal barrier, alters the homeostatic balance between gastrointestinal bacteria and gut immunity, and induces changes in the composition of the gut microbiota, leading to enrichment and depletion of proinflammatory or potentially pathogenic bacterial populations such as Pseudomonas aeruginosa and Candida albicans, and the reduction of Bifidobacteria levels and Lactobacillus species These deleterious changes may lead to microbial translocation and loss of gut homeostasis.
Probiotics as a New Therapeutic Approach for HIV
Given the critical role of reducing bacterial translocation and proinflammatory cytokine production in maintaining intestinal homeostasis, new therapies aimed at restoring epithelial and gut-associated lymphoid tissue (GALT) integrity and improving chronic immune activation through oral administration of prebiotics, probiotics, or synbiotics are promising new strategies to mitigate disease progression in patients with HIV. An increasing number of studies have attempted to demonstrate that the use of probiotics, prebiotics, and synbiotics may help to protect immune function in HIV patients, thereby preventing CD4+ T cell depletion. Many studies and clinical trials have evaluated the effect of administering probiotics (dietary supplements containing live bacteria) to HIV-positive individuals, often with promising positive results. Probiotic supplements may help prevent diarrhea and reestablish a normal gut microbiome in HIV-positive patients.
Fig.1 Current therapeutic modalities to repair mucosal damage during HIV and SIV infection.1
Mechanisms
Probiotics may interfere with HIV through a variety of mechanisms. It can compete for nutrients and epithelial and mucosal adhesion, inhibit epithelial invasion, combat inflammatory processes by stabilizing and strengthening the intestinal flora responsible for the integrity of the intestinal barrier, prevent microbial translocation, reduce mucosal and systemic inflammation, stimulate the production of antimicrobial substances, and promote the intestinal immunoglobulin A response to improve immune barrier function.
Fig.2 Beneficial effects of probiotics in the GI tract of HIV-1-infected patients.
Our Probiotic Services for HIV Research
|
Research Articles
|
Available Services
|
|
Effect of probiotic supplement on cytokine levels in HIV-infected individuals: a preliminary study.2
|
|
|
Inhibition of HIV and HSV infection by vaginal lactobacilli in vitro and in vivo.3
|
|
|
Antifungal effects of Lactobacillus acidophilus and Lactobacillus plantarum against different oral Candida species isolated from HIV/ AIDS patients.4
|
|
Creative Biolabs is a leading global probiotics contract research organization that provides customized services and products for preclinical research in multiple areas of probiotics therapy, including HIV research. From the isolation and identification of probiotics to safety assessment and customized production, we have the rich project experience to develop reasonable and efficient solutions for you. If you are interested in our services, please feel free to contact us for more details.
References
-
Crakes, Katti R., and Guochun Jiang. "Gut microbiome alterations during HIV/SIV infection: implications for HIV cure." Frontiers in microbiology 10 (2019): 1104.
-
Falasca, Katia, et al. "Effect of probiotic supplement on cytokine levels in HIV-infected individuals: a preliminary study." Nutrients 7.10 (2015): 8335-8347.
-
Zabihollahi, Rezvan, et al. "Inhibition of HIV and HSV infection by vaginal lactobacilli in vitro and in vivo." DARU Journal of Pharmaceutical Sciences 20 (2012): 1-7.
-
Salari, Samira, and Pooya Ghasemi Nejad Almani. "Antifungal effects of Lactobacillus acidophilus and Lactobacillus plantarum against different oral Candida species isolated from HIV/AIDS patients: an in vitro study." Journal of oral microbiology 12.1 (2020): 1769386.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
